US Voters Are Pessimistic about the ACA, with 3 out of 4 Expecting Healthcare Quality, Access and Costs to Remain the Same or

US Voters Are Pessimistic about the ACA, with 3 out of 4 Expecting Healthcare
Quality, Access and Costs to Remain the Same or Get Worse after Implementation

New WG Consulting Research Reveals Romney Voters Are Most Negative, while the
Uninsured Have the Highest Hopes

PR Newswire

NEW YORK, Dec. 5, 2012

NEW YORK, Dec. 5, 2012 /PRNewswire/ -- With the Affordable Care Act (ACA) set
to go into effect in 2014, most US voters remain pessimistic about healthcare,
according to new research from WG Consulting, a division of ghg. Three out of
four anticipate that the cost and quality of care, access to medications and
doctors, availability of treatment innovations, and insurance costs and
coverage all will stay the same or get worse. Those who voted for Romney are
more likely than Obama supporters to believe they will see the overall quality
of healthcare decline when the ACA is implemented.

In contrast, the uninsured are most optimistic about the ACA, with 1 in 3
expecting an improvement in the quality of care, compared to just 1 in 5
insured voters. In addition, more than twice as many uninsured voters as
insured voters think they will be better off in terms of insurance coverage
and costs, as a result of the ACA.

"Voters are divided on many aspects of the ACA, with cost of care an issue
where we see particularly wide gaps among segments," says Claire Gillis, CEO
of WG Consulting. "Almost half of Obama voters believe the election results
will leave them better off in terms of cost of care, while just 6% of Romney
supporters would agree with that positive outlook. In addition, twice as many
African American and Hispanic voters as white voters think they will see
improvements on cost of care, with Obama returning to the White House. There
also are major differences among age groups, with 39% of voters under 35
anticipating cost of care will get better -- a view shared by just 19% of
those 50 and older. It will be important to continue monitoring voters to see
how perceptions change as the ACA becomes reality -- and if experiences with
the ACA closes or widens the gaps among audiences."

Voters Want Pharmaceutical Companies to Play an Active Role in Reforming

Voters want to see pharmaceutical companies actively involved in improving
healthcare. Three-quarters of voters think it's extremely important for the
pharmaceutical industry to be involved in controlling/reducing drug costs. In
addition, almost two-thirds place the highest importance on pharmaceutical
manufacturers working more closely with doctors to improve patients' health
outcomes -- and more than half feel strongly that pharma should provide more
patient assistance programs for those in financial need. Almost half place
extreme importance on pharma serving as an advocate to expand patient access
to drugs.

"In earlier research we performed with physicians, payers and pharmaceutical
companies, respondents were split 50/50 on whether it's pharma's job to help
with ACA implementation and healthcare reforms," says Lynn O'Connor Vos, CEO
of ghg. "In contrast, consumers feel strongly that pharma has a key role to
play, with communications being one of the primary ways they'd like to see
pharmaceutical companies participate in improving healthcare.

"More than 80% think it's extremely or somewhat important for pharmaceutical
companies to produce educational materials on healthcare reforms for
consumers, as well as to create web sites and literature for patients on their
conditions and treatment options. In addition, three-quarters put importance
on providing apps to help sufferers better manage their conditions. Our
research shows a clear 'call-to-action' for pharma to be part of the
healthcare solution -- not only in developing treatment innovations but in
providing information, guidance and support."

More than 1200 Voters Participate

The WG Consulting research was part of the 2012 Penn Schoen Berland (PSB)
National Post-Election Study. The online study was conducted among 1,202
American voters on November 9 and 10, 2012.

About WG Consulting

WG Consulting, part of the ghg network, is a global, evidence-based,
best-in-class market access consultancy, aligning clinical, HEOR and payer
analytics across all therapeutic categories and every stage of the drug
commercialization process. It provides value-driven, integrated, market
access solutions and guidance, helping clients effectively communicate brand
value to clinical and payer stakeholders and optimize patient outcomes. A
worldwide leader, WG recently opened a new US office at 114 Fifth Avenue, New

About PSB

Penn Schoen Berland (PSB), a member of WPP Group, is a global research-based
consultancy that specializes in strategy, positioning and messaging with key
stakeholders. With offices in the US, the UK, and Asia, PSB has conducted
thousands of market research studies to gather evidence to advise our clients
on how to optimize the success of marketing and commercialization. PSB's
Healthcare Practice works across the healthcare ecosystem from discovery to
healthcare delivery, helping clients achieve their business and policy goals
and advance medicine and health.


Contact: Stacy Thompson, +1-212-886-3058,, or Ilene
Siegalovsky, +1-212-886-3151,, both of ghg
Press spacebar to pause and continue. Press esc to stop.